Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp, Cladribine, and Cytarabine in CD123+ Relapsed/Refractory AML
NCT06561152Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Feb 2025
- Primary completion
- Oct 2027
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of tagraxofusp in acute myeloid leukemia (AML), sponsored by Stanford University. Started Feb 2025; status: recruiting.
02
Drugs
tagraxofusp
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06561152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561152.